PRICED Act

Summary

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 18 May 2022

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 18 May 2022

   Introduced

   Introduced in House

   Source: IntroReferral

3. 18 May 2022

   Introduced

   Introduced in House

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 18 May 2022 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 18 May 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 18 May 2022

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 18 May 2022

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
• Rep. Westerman, Bruce [R-AR-4] · R · Sponsor
• Rep. Khanna, Ro [D-CA-17] · D · Sponsor
• Rep. Doggett, Lloyd [D-TX-37] · D · Sponsor
• Rep. Pocan, Mark [D-WI-2] · D · Sponsor
• Rep. Kaptur, Marcy [D-OH-9] · D · Sponsor
• Rep. García, Jesús G. "Chuy" [D-IL-4] · D · Sponsor
• Rep. DeLauro, Rosa L. [D-CT-3] · D · Sponsor
• Rep. Krishnamoorthi, Raja [D-IL-8] · D · Cosponsor
• Rep. Levin, Andy [D-MI-9] · D · Cosponsor
• Rep. Jayapal, Pramila [D-WA-7] · D · Cosponsor
• · hsif00 · Standing

Related records

• related to → Affordable Medications Act
• related to ← Fair Care Act of 2022
• related to ← PRICED Act